Please assess the completion status of the following clinical trial:

Trial Title: NSAID Treatment in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Patients eligible for the study were:~* older than 50 years and~* had primary knee OA diagnosed according to the clinical and radiological criteria of the American Rheumatism Association.~Further inclusion criteria were:~* clinical signs of joint inflammation (warmth, swelling or effusion) and~* a disease severity grade 2 or 3 according to the Kellgren-Lawrence classification~Exclusion Criteria:~* allergy to NSAIDs,~* progressive serious medical conditions (such as cancer, AIDS or end-stage renal disease),~* history of gastrointestinal ulcer or bleeding,~* a hemoglobin concentration lower than 11.5 g/dL,~* renal diseases (serum creatinine concentration more than 1.2 times the upper limit of the normal range according to the central laboratory definition reference values), or~* liver dysfunction (serum alanine or aspartate transaminase concentrations more than 1.5 times the upper limit of normal range according to the central laboratory definition reference values).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- diclofenac 75 mg/day (Type: ACTIVE_COMPARATOR): diclofenac 75 mg once day slow release
- diclofenac 150 mg/day (Type: ACTIVE_COMPARATOR): diclofenac 75 mg bid
- ibuprofen 1200 mg/day (Type: ACTIVE_COMPARATOR): ibuprofen 600 mg bid
- ibuprofen 1800 mg/day (Type: ACTIVE_COMPARATOR): ibuprofen 600 mg tid
- celecoxib 200 mg/day (Type: ACTIVE_COMPARATOR): celecoxib 200 mg once day
- celecoxib 400 mg/day (Type: ACTIVE_COMPARATOR): celecoxib 200 mg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).